Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2018

View Archived Issues

Japan AMED selects FunPep project for orphan drug support program

First subjects dosed in first-in-human study of TransCon CNP

Pfizer reports regulatory and pipeline highlights of first quarter 2018

Development of Wayshine Biopharm compounds advances for brain and lung cancer

Novel Ironwood soluble guanylate cyclase stimulator reduces neuroinflammation

AcelRx Pharmaceuticals resubmits Dsuvia NDA in U.S.

IGEM Therapeutics awarded grant from Innovate UK

Provention Bio acquires rights to teplizumab and MGD-010 from MacroGenics

Lipocine receives FDA complete response letter for Tlando

Novel NKCC1 inhibitor reduces brain damage after ischemic stroke in mice

Escient Pharmaceuticals launches to advance first-in-class GPCR-targeted drugs

Lodo Therapeutics and Genentech enter multi-target strategic collaboration

Syndax Pharmaceuticals describes preclinical activity of Menin/MLL1 inhibitor VTP-50469

Lundbeck updates pipeline progress of first quarter 2018

New EAAT3 inhibitors divulged by Roche

Regeneron presents novel REGN-4018 antibody for ovarian cancer

Novartis patents novel HBV HBsAg secretion inhibitors

CSIC, University of Glasgow present trypanosomal alternative oxidase inhibitors

Phase III study of Tecentriq and Cotellic in metastatic colorectal cancer misses primary endpoint

Forma Therapeutics collaborates with University of Oxford on deubiquitinating enzyme inhibitors

Astellas licenses rights to Aquinox's rosiptor in Japan and Asia-Pacific countries

MediciNova cleared to study ibudilast for glioblastoma

Sellas' galinpepimut-S awarded FDA orphan drug designation for multiple myeloma

FDA grants orphan drug designation to Cellectar's CLR-131 for rhabdomyosarcoma

YL Biologics and Kyowa submit Japanese NDA for etanercept biosimilar YLB-113

Gilead studies GS-9688 in virally suppressed patients with chronic HBV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...